In myocardial infarction, ischemia-reperfusion injury, cardiac remodeling, and myocarditis, inhibiting RIPK1/3 would interrupt the transmission of inflammatory signals, thereby reducing the damage and remodeling of cardiomyocytes. Here, RIPK1 is linked to myocarditis.